Patricia Villagrasa

4PUBLICATIONS
75CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (4)

|Aug 20, 2026
Pathologic Complete Response (pCR) Rate and Predictors of Response to Taxane, Trastuzumab, and Pertuzumab in HER2‑Positive Breast Cancer: Secondary Analyses of EA1181/CompassHER2 pCR.

|Dec 03, 2025
Palbociclib, Trastuzumab, and Endocrine Therapy in Pretreated HER2-Positive and PAM50 Luminal Advanced Breast Cancer: Randomized Phase II, SOLTI-1303 PATRICIA Trial.

Eva Ciruelos, Tomás Pascual, Guillermo Villacampa

|Dec 01, 2025
Associations of the HER2DX Genomic Test with Biological and Pathologic Features in HER2-Positive Breast Cancer.

Esther Sanfeliu, Anabel Martínez-Romero, Mercedes Marín-Aguilera

|Jul 12, 2024
HER2DX Genomic Assay in HER2-Positive Early Breast Cancer Treated with Trastuzumab and Pertuzumab: A Correlative Analysis from the PHERGain Phase II Trial.

Antonio Llombart-Cussac, Jose Pérez-García, Fara Brasó-Maristany

Pageof 1

Frequent Collaborators

3 joint publications

Javier Cortés

3 joint publications

Aleix Prat

2 joint publications

Esther Sanfeliu

2 joint publications

Fara Brasó-Maristany